Yun-fei Yuan

651 Dongfeng Rd
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

Local Control in a Retrospective Series of Magnetic Resonance Guided Stereotactic Body Radiation Therapy for Colorectal Liver Metastases: A Single-Institution Experience.

Local Control in a Retrospective Series of Magnetic Resonance Guided Stereotactic Body Radiation Therapy for Colorectal Liver Metastases: A Single-Institution Experience.

Journal: Practical radiation oncology

Published: November 18, 2025

Vessels encapsulating tumor clusters promote noninvasive metastasis of hepatocellular carcinoma by shaping an immunosuppressive microenvironment.

Vessels encapsulating tumor clusters promote noninvasive metastasis of hepatocellular carcinoma by shaping an immunosuppressive microenvironment.

Journal: The Journal of clinical investigation

Published: March 26, 2025

Erratum: Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression: Erratum.

Erratum: Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression: Erratum.

Journal: Theranostics

Published: February 03, 2025

ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA.

ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: January 14, 2025

Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial.

Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 01, 2024

Percutaneous hepatic artery infusion chemotherapy with oxaliplatin and fluoropyrimidines in treatment-resistant colorectal cancer patients with unresectable liver metastases: a retrospective cohort study.

Percutaneous hepatic artery infusion chemotherapy with oxaliplatin and fluoropyrimidines in treatment-resistant colorectal cancer patients with unresectable liver metastases: a retrospective cohort study.

Journal: HPB : the official journal of the International Hepato Pancreato Biliary Association

Published: June 20, 2024

m6A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma.

m6A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 23, 2024

AXIN1 boosts antiviral response through IRF3 stabilization and induced phase separation.

AXIN1 boosts antiviral response through IRF3 stabilization and induced phase separation.

Journal: Signal transduction and targeted therapy

Published: April 22, 2024

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

Journal: PLoS medicine

Published: December 01, 2023

Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS/STING signaling.

Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS/STING signaling.

Journal: Nature communications

Published: November 17, 2023

TSPO is a novel biomarker for prognosis that regulates cell proliferation through influencing mitochondrial functions in HCC.

TSPO is a novel biomarker for prognosis that regulates cell proliferation through influencing mitochondrial functions in HCC.

Journal: Heliyon

Published: March 03, 2023

A detailed assessment of liver function in patients with hepatocellular carcinoma via the modified albumin-bilirubin (mALBI) grade.

A detailed assessment of liver function in patients with hepatocellular carcinoma via the modified albumin-bilirubin (mALBI) grade.

Journal: American journal of cancer research

Published: March 13, 2022

Showing 1-12 of 81

Last Updated: 09/26/2026